Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1501-1507

  Mandai, M ^a   Konishi, I ^a   Kuroda, H ^a   Fukumoto, M ^a   Komatsu, T ^a   Yamamoto, S ^a   Nanbu, K ^a   Rao, Ch V ^b   Mori, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT;

ARTICLE; EPITHELIUM TUMOR; EXON; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION;

FEMALE; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; OVARIAN NEOPLASMS; OVARY; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, LH; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0030850682     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00166-4     Document Type: Article

References (61)

1. Segaloff DL, Ascoli M. The lutropin/choriogonadotropin receptor: 4 years later. Endocrine Rev 1993, 14, 324-347.
2. Loosfelt H, Misrahi M, Atger M, et al. Cloning and sequencing of porcine LH-hCG receptor cDNA: variants lacking transmembrane domain. Science 1989, 245, 525-528.
3. 2 + mobilization. J Biol Chem 1992, 267, 4479-4488.
4. McFarland KC, Sprengel R, Phillips HS, et al. Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family. Science 1989, 245, 494-499.
5. Minegishi T, Nakamura K, Takakura Y, et al. Cloning and sequencing of human LH/hCG receptor cDNA. Biochem Biophys Res Commun 1990, 172, 1049-1054.
6. Tsai-Morris CH, Buczko E, Wang W, Xie X-Z, Dufau ML. Structural organization of the rat luteinizing hormone (LH) receptor gene. J Biol Chem 1991, 266, 11355-11359.
7. Frazier AL, Robbins LS, Stork PJ, Sprengel R, Segaloff DL, Cone RD. Isolation of TSH and LH/CG receptor cDNA from human thyroid: regulation by tissue specific splicing. Mol Endocrinol 1990, 4, 1264-1276.
8. Sokka T, Hamalainen T, Huhtaniemi I. Functional LH receptor appears in the neonatal rat ovary after changes in the alternative splicing pattern of the LH receptor mRNA. Endocrinology 1992, 130, 1738-1740.
9. Nishimori K, Dunkel L, Hsueh AJW, Yamoto M, Nakano R. Expression of luteinizing hormone and chorionic gonadotropin receptor messenger ribonucleic acid in human corpora lutea during menstrual cycle and pregnancy. J Clin Endocrinol Metab 1995, 80, 1444-1448.
10. Lei ZM, Toth P, Rao CV, Pridham D. Novel coexpression of human chorionic gonadotropin (hCG)/human luteinizing hormone receptors and their ligand hCG in human fallopian tubes. F Clin Endocrinol Metab 1993, 77, 863-872.
11. Környei JL, Lei ZM, Rao CV. Human myometrial smooth muscle cells are novel targets of direct regulation by human chorionic gonadotropin. Biol Reprod 1993, 49, 1149-1157.
12. Lei ZM, Rao CV, Környei JL, Licht P, Hiatt ES. Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. Endocrinology 1993, 132, 2262-2270.
13. Lin J, Lei ZM, Lojun S, Rao CV, Satyaswaroop PG, Day TG. Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas. J Clin Endocrinol Metab 1994, 79, 1483-1491.
14. Lei ZM, Rao CV, Ackerman DM, Day TG. The expression of human chorionic gonadotropin/human luteinizing hormone receptors in human gestational trophoblastic neoplasms. J Clin Endocrinol Metab 1992, 74, 1236-1241.
15. Longo DL, Young RC. The natural history and treatment of ovarian cancer. Ann Rev Med 1981, 32, 475-490.
16. Bristow RE, Karlan BY. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 1996, 8, 32-37.
17. Rajaniemi H, Kaupilla A, Rönnberg L, Selander K, Pystynen P. LH(hCG) receptor in benign and malignant tumors of human ovary. Acta Obstet Gynecol Scand (Suppl) 1981, 101, 83-86.
18. Kammerman S, Demopoulos RI, Raphael C, Ross J. Gonadotropic hormone binding to human ovarian tumors. Hum Pathol 1981, 12, 886-890.
19. Stouffer RL, Grodin MS, Davis JR, Surwit EA. Investigation of binding sites for follicle-stimulating hormone and chorionic gonadotropin in human ovarian cancers. J Clin Endocrinol Metab 1984, 59, 441-446.
20. Nakano R, Kitayama R, Yamoto M, Shima K, Ooshima A. Localization of gonadotropin binding sites in human ovarian neoplasms. Am J Obstet Gynecol 1989, 161, 905-910.
21. FIGO. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987, 156, 263-265.
22. Chomczynski P, Sacchi N. Single step method of RNA isolation by guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162, 156-159.
23. Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-J genes, and sex steroid receptor expression. Cancer Res 1994, 54, 1825-1830.
24. Tsai-Morris CH, Buczko E, Wang W, Dufau ML. Intronic nature of the rat luteinizing hormone receptor gene defines a soluble receptor subspecies with hormone binding activity. J Biol Chem 1990, 265, 19385-19388.
25. Smith CWJ, Patton JG, Nadal-Ginard B. Alternative splicing in the control of gene expression. Ann Rev Genet 1989, 23, 527-577.
26. Koo-YB, Ji-I, Ji-TH. Characterization of different sizes of rat luteinizing hormone/chorionic gonadotropin receptor messenger ribonucleic acids. Endocrinology 1994, 134, 19-26.
27. Bacich DJ, Rohan RM, Norman RJ, Rodgers RJ. Characterization and relative abundance of alternatively spliced luteinizing hormone receptor messenger ribonucleic acid in the ovine ovary. Endocrinology 1994, 135, 735-744.
28. Aatsinki JT, Pietilä EM, Lakkakorpi JT, Rajaniemi HJ. Expression of the LH/CG receptor gene in rat ovarian tissue is regulated by an extensive alternative splicing of the primary transcript. Mol Cell Endocrinol 1992, 84, 127-135.
29. Tena-Sempere M, Zhang F-P, Huhtaniemi I. Persistent expression of a truncated form of the luteinizing hormone receptor messenger ribonucleic acid in the rat testis after selective Leydig cell destruction by ethylene dimethane sulfonate. Endocrinology 1994, 135, 1018-1024.
30. Davis JS. Mechanisms of hormone action: luteinizing hormone receptor and second-messenger pathway. Curr Opin Obstet Gynecol 1994, 6, 254-261.
31. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res 1995, 55, 2158-2165.
32. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995, 55, 1441-1443.
33. Wu Y, Liu Y, Lee L, Miner Z, Kulesz-Martin M. Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO J 1994, 13, 4823-4830.
34. Whittemore AS, Harris R, Itnyre J, Halpern J, the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992, 136, 1175-1220.
35. Balasch J, Barri PN. Follicular stimulation and ovarian cancer? Hum Reprod 1993, 8, 990-996.
36. Cohen J, Forman R, Harlap S, et al. IFFS expert group report on the Whittemore study related to the risk of ovarian cancer associated with the use of infertility agents. Hum Reprod 1993, 8, 996-999.
37. Shoham Z. Epidemiology, etiology and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 1994, 62, 433-448.
38. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994, 331, 771-776.
39. Franceschi S, La Vacachia C, Negri E, et al. Fertility drugs and risk of ovarian cancer in Italy. Hum Reprod 1994, 9, 1673-1675.
40. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995, 27, 1926-1930.
41. Shushan A, Elchalal U, Paltiel O, Peretz T, Iscovich J, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996, 65, 13-18.
42. Venn A, Watson L, Lumley J, Giles G, King C, Haly D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995, 346, 995-1000.
43. Zheng W, Magid MS, Kramer EE, Chen Y-T. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 1996, 148, 47-53.
44. Bamford PN, Steele SJ. Uterine and ovarian carcinoma in a patient receiving gonadotropin therapy. Case report. Br J Obstet Gynaecol 1982, 89, 962-964.
45. Atlas M, Menczer J. Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta Obstet Gynecol Scand 1982, 61, 261-263.
46. Ben-Hur H, Dagni R, Lancet M, et al. Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta Obstet Gynecol Scand 1986, 65, 813-814.
47. Carter ME, Joyce DN. Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization. A case report. J In Vitro Fertil Embryo Trans 1987, 4, 126-128.
48. Kulkarni R, McGarry JM. Follicular stimulation and ovarian cancer. Br Med J 1989, 299, 740.
49. Dietl J. Ovulation and ovarian cancer. Lancet 1991, 338, 445.
50. Nijman HW, Burger CW, Baak JPA, Schats R, Vermorken JB, Kenemans P. Borderline malignancy of the ovary and controlled hyperstimulation. A report of 2 cases. Eur J Cancer 1992, 28A, 1971-1973.
51. Goldberg GL, Runowicz CD. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation. Is there a link? Am J Obstet Gynecol 1992, 166, 853-854
52. Karlan BY, Marrs R, Lagasse LD. Advanced stage ovarian carcinoma presenting during infertility evaluation. Am J Obstet Gynecol 1994, 171, 1377-1378.
53. Grimbizis G, Tarlatzis BC, Bontis J, et al. Two cases of ovarian tumours in women who had undergone multiple ovarian stimulation attempts. Hum Reprod 1995, 10, 520-523.
54. Komatsu T, Konishi I, Mandai M, et al. Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: immunohistochemical expression of LH/hCG receptors. Gynecol Oncol 1995, 56, 470-474.
55. Bandera CA, Cramer DW, Friedman AJ, Sheets EE. Fertility therapy in the setting of a large history of invasive epithelial ovarian cancer. Gynecol Oncol 1995, 58, 116-119.
56. Kobayashi F, Monma C, Nanbu K, et al. Rapid growth of an ovarian clear cell carcinoma expressing LH/hCG receptor arising from endometriosis during early pregnancy. Gynecol Oncol 1996, 62, 309-313.
57. Simon WE, Albrecht M, Hänsel M, Dietel M, Hözel F. Cell lines derived from human ovarian carcinomas.: growth stimulation by gonadotrophic and steroid hormones. J Natl Cancer Ins 1983, 70, 839-844.
58. Wimalasena J, Dostal R, Meehan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol Oncol 1992, 46, 345-350.
59. Ohtani K, Sakamoto H, Sato K. Stimulatory effects of follicular stimulating hormone on the proliferation of ovarian cancer cell line in vitro and in vivo. Acta Obstet Gynaecol Jpn 1992, 44, 717-724.
60. Kataoka A, Nishida T, Motomura S, et al. The effects of sex steroid hormones, gonadotropins, and gonadotropin releasing hormone agonist on the proliferation of ovarian cancer cell line (KOC-2S). Acta Obstet Gynaecol Jpn 1994, 46, 1033-1040.
61. Magoffin DA, Weitsman SR. Insulin-like growth factor-I regulation of luteinizing hormone (LH) receptor messenger ribonucleic acid expression and LH-stimulated signal transduction in rat ovarian theca-interstitial cells. Biol Reprod 1994, 51, 766-775.